Literature DB >> 21858539

Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review.

Luis Calzadilla Bertot1, Masaya Sato, Ryosuke Tateishi, Haruhiko Yoshida, Kazuhiko Koike.   

Abstract

OBJECTIVES: Reported rates of major complications and mortality of radiofrequency ablation (RFA), microwave ablation (MWA) and percutaneous ethanol injection (PEI) for the treatment of liver tumours were substantially heterogeneous among studies. The aim was to analyse the mortality and major complication rates of percutaneous RFA, PEI and MWA.
METHODS: MEDLINE and EMBASE search from January 1982 to August 2010. Randomised clinical trials and observational studies, age >18, more than 50 patients for each technique analysed, studies reporting mortality and major complications were included. Random effects model was performed, with assessment for heterogeneity and publication bias.
RESULTS: Thirty-four studies including 9531, 1185, and 1442 patients for RFA, MWA, and PEI, respectively were included. For all ablative techniques pooled proportion mortality rate was 0.16% (95% confidence interval [CI], 0.10-0.24). Pooled mortality rate associated with RFA, PEI and MWA was 0.15% (0.08-0.23), 0.59% (0.14-1.3) and 0.23% (0.0-0.58) respectively. Pooled proportion of major complications was 3.29% (2.43-4.28). Major complication rates associated with RFA, MWA, and PEI was 4.1% (3.3-5.1), 4.6% (0.7-11.8) and 2.7% (0.28-7.4) respectively.
CONCLUSIONS: Percutaneous RFA, PEI and MWA can be considered safe techniques for the treatment of liver tumours.

Entities:  

Mesh:

Year:  2011        PMID: 21858539     DOI: 10.1007/s00330-011-2222-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  65 in total

Review 1.  Loco-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 2.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

3.  Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.

Authors:  Chandrajit P Raut; Francesco Izzo; Paolo Marra; Lee M Ellis; Jean-Nicolas Vauthey; Francesco Cremona; Paolo Vallone; Angelo Mastro; Bruno D Fornage; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2005-06-20       Impact factor: 5.344

4.  Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients.

Authors:  A Giorgio; L Tarantino; G de Stefano; A Perrotta; V Aloisio; L del Viscovo; A Alaia; G Lettieri
Journal:  Eur J Ultrasound       Date:  2000-12

5.  Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings.

Authors:  Hyunchul Rhim; Kwon-Ha Yoon; Jeong Min Lee; Yoonkoo Cho; June-Sik Cho; Seung Hoon Kim; Won-Jae Lee; Hyo Keun Lim; Gyoung-Jin Nam; Sang-Suk Han; Yun Hwan Kim; Cheol Min Park; Pyo Nyun Kim; Jae-Young Byun
Journal:  Radiographics       Date:  2003 Jan-Feb       Impact factor: 5.333

6.  Radiofrequency thermal ablation with expandable needle of focal liver malignancies: complication report.

Authors:  Elisabetta Buscarini; Luigi Buscarini
Journal:  Eur Radiol       Date:  2003-10-17       Impact factor: 5.315

7.  Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

Authors:  W L Tsai; J S Cheng; K H Lai; C P Lin; G H Lo; P I Hsu; H C Yu; C K Lin; H H Chan; W C Chen; T A Chen; W L Li; H L Liang
Journal:  Aliment Pharmacol Ther       Date:  2008-08-01       Impact factor: 8.171

8.  Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation.

Authors:  Andrea Ruzzenente; Giovanni De Manzoni; Matteo Molfetta; Silvia Pachera; Bruno Genco; Matteo Donataccio; Alfredo Guglielmi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

9.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

Authors:  T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

10.  Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients--mathematic model, overlapping mode, and electrode placement process.

Authors:  Min-Hua Chen; Wei Yang; Kun Yan; Ming-Wu Zou; Luigi Solbiati; Ji-Bin Liu; Ying Dai
Journal:  Radiology       Date:  2004-05-27       Impact factor: 11.105

View more
  59 in total

Review 1.  Microwave ablation of hepatocellular carcinoma.

Authors:  Guido Poggi; Nevio Tosoratti; Benedetta Montagna; Chiara Picchi
Journal:  World J Hepatol       Date:  2015-11-08

2.  Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years.

Authors:  Antonio Giorgio; Maria G Merola; Luca Montesarchio; Francesca Merola; Pietro Gatti; Carmine Coppola; Valentina Giorgio; Giorgio Calisti
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

Review 3.  New Approaches in Locoregional Therapies for Hepatocellular Carcinoma.

Authors:  Riccardo Memeo; Vito de Blasi; Zineb Cherkaoui; Ammar Dehlawi; Nicola De' Angelis; Tullio Piardi; Daniele Sommacale; Jacques Marescaux; Didier Mutter; Patrick Pessaux
Journal:  J Gastrointest Cancer       Date:  2016-09

Review 4.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

5.  Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy : Complications and risk factors.

Authors:  Konrad Mohnike; Steffen Wolf; Robert Damm; Max Seidensticker; Ricarda Seidensticker; Frank Fischbach; Nils Peters; Peter Hass; Günther Gademann; Maciej Pech; Jens Ricke
Journal:  Strahlenther Onkol       Date:  2016-02-29       Impact factor: 3.621

Review 6.  Complications of image-guided thermal ablation of liver and kidney neoplasms.

Authors:  Kyung Rae Kim; Sarah Thomas
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 7.  Microwave ablation of hepatic malignancy.

Authors:  Meghan G Lubner; Christopher L Brace; Tim J Ziemlewicz; J Louis Hinshaw; Fred T Lee
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

8.  Recurrence after microwave ablation of liver malignancies: a single institution experience.

Authors:  Ryan T Groeschl; Ray K Wong; Edward J Quebbeman; Susan Tsai; Kiran K Turaga; Sam G Pappas; Kathleen K Christians; Eric J Hohenwalter; Sean M Tutton; William S Rilling; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2012-10-11       Impact factor: 3.647

9.  Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience.

Authors:  Ashraf Abdelaziz; Tamer Elbaz; Hend Ibrahim Shousha; Sherif Mahmoud; Mostafa Ibrahim; Ahmed Abdelmaksoud; Mohamed Nabeel
Journal:  Surg Endosc       Date:  2014-06-17       Impact factor: 4.584

Review 10.  Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law.

Authors:  Gerond Lake-Bakaar; Muneeb Ahmed; Amy Evenson; Alan Bonder; Salomao Faintuch; Vinay Sundaram
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.